[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"PharmaEssentia Japan K.K.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100412787","phase-3-extension-study-of-p1101-after-completion-of-phase-2-study-in-pv-patients-or-phase-3-study-in-et-patients-100412787",false,"NCT04655092","Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","Extension Study of P1101 in Japanese Patients Who Have Completed Phase 2 Single Arm Study in Polycythemia Vera (PV) Patients (Study A19-201) or Phase 3 Study in Essential Thrombocythemia (ET) Patients (Study P1101 ET)","Inclusion Criteria:\n\n* Patients who have completed the 52-week treatment duration in Study A19-201 and are considered by the investigator or sub investigator to be eligible for participation in this study\n* Patients who have given written informed consent to participate in this study\n\nExclusion Criteria:\n\n* Patients who are considered by the investigator or sub investigator to be ineligible for continued treatment with P1101","ALL","20 Years",{"count":19,"type":20},67,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.",[26],"Polycythemia Vera (PV)",[28],"Myeloproliferative Neoplasms","RECRUITING","2024-11-06",{"date":32,"type":33},"2024-11-08","ACTUAL",{"date":35,"type":33},"2021-01-19",{"date":37,"type":20},"2026-06-30",{"name":39,"class":40},"PharmaEssentia Japan K.K.","INDUSTRY",6,""]